Hovhannes J. Gukasyan

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 456 citations · Full text

Drug Target, Health Sciences, Preclinical Models +10

Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis.

Mohamed G. Qaddoumi, Hovhannes J. Gukasyan, Jasmine Davda et al. · PubMed · 2003 · 139 citations

Eyes on Lipinski's Rule of Five: A New “Rule of Thumb” for Physicochemical Design Space of Ophthalmic Drugs

Thomas K. Karami, Shumet Hailu, Shaoxin Feng et al. · Journal of Ocular Pharmacology and Therapeutics · 2021 · 126 citations · Full text

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)

Pei‐Pei Kung, Patrick Bingham, Alexei Brooun et al. · Journal of Medicinal Chemistry · 2017 · 125 citations · Full text

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

Pei‐Pei Kung, Eugene Rui, Simon Bergqvist et al. · Journal of Medicinal Chemistry · 2016 · 66 citations · Full text